Company Facts

Founded in 2011

Based in the Netherlands

Privately owned


APO-T was founded in 2011 by Dr. Ralph Willemsen (in Memoriam)  and JPWaVe BV.  Dr. Willemsen had been investigating tumor apoptosis at the Medical Centre of the Erasmus University Rotterdam, one of the largest academic hospitals in the world, for many years and has been focused on the development of the new cancer-specific therapeutic molecules currently in our portfolio since APO-T’s inception.

The founders of APO-T saw the therapeutic and commercial potential of Dr. Willemsen’s technology and knowledge with respect to the targeting of the HLA-MAGE peptide complexes shown to be exclusively exposed by cancer cells as well as the potential of the treatment format (Apoptosis Inducing Molecules: AIMs).